glp 1 agonist crohn's disease GLP-1 with Disease: Safety, Risks and Clinical Guidance – Bolt Pharmacy GLP-1 Agonists and Crohn's Disease:

Dethlefsen, L., Huse, S., Sogin, M

2004 Oct 8;279(41):42726-31

(2014) Impact of surfactant protein D, interleukin-5, and eosinophilia on Cryptococcosis Infect

Sample name: the product of the invention (batch number P-110201, specification 0.6g) Preparing a compatible injection: 0.9% sodium chloride injection, manufactured by Chongqing Di kang Yangtze pharmaceutical Co., Ltd 5% glucose injection, manufactured by Tai Ji southwest pharmaceutical industries, Ltd 10% glucose injection, manufactured by Tai Ji southwest pharmaceutical industries, Ltd Water for injection, made by Investigation time: 0h, 2h, 4h and 6h And (4) investigation indexes are as follows: the results of the product of the invention in four injections at ambient temperature conditions (dilution to measured concentration, measured only at 0h, 2h, 4h, 6 h) for clarity, pH, visible foreign matter, insoluble particles, related substances (area normalization) are shown in tables 7-8